HM11260C
Phase 3Small molecule
Hanmi Pharmaceutical Company LimitedHM11260C is one of 115 small molecule programs targeting Type 2 Diabetes Mellitus. It is currently in Phase 3.
4
Indications
8
Total Trials
1
Active Trials
114
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
885 competitors in Type 2 Diabetes
#DrugCompanyPhaseTrials
1HM11260C
Hanmi Pharmaceutical Company LimitedPhase 3
Byetta
AstraZenecaPreclinical
Glargine
Eli LillyPreclinical
Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Pravachol
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
Forxiga
AstraZenecaPreclinical
Acipimox
Boehringer IngelheimPreclinical
SGLT-2 Inhibitor
SSheffield Teaching Hospitals NHS Foundation Trust
Preclinical
Antiplatelet Drug
FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Preclinical
Insulins
Eli LillyPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Type 2 Diabetes Mellitus3 trials
Type 2 Diabetes2 trials
Obesity1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HM11260C. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details